Who We Are?

Our Mission

Cancer is the major healthcare challenge worldwide.

The conventional treatment of cancer has been with broad spectrum cytotoxic chemotherapeutic drugs. They have offered varied success but have many undesirable side effects.

The last decade has witnessed a paradigm shift in both cancer research and therapy with the T cell-based immunotherapies. T cells are a vital component of adaptive immunity. They function in a targeted manner using specific surface receptors called TCRs. Using this unique property, T cells can be made to efficiently target tumors with engineered receptors called CARs.

We at Celliimune, harness our deep understanding and expertise in stem cell biology, immunology, genetic engineering, protein engineering and clinical oncology to develop an innovative iPSC-based, allogeneic, engineered immune cells including but not limited to T cell therapy (CAR-T) platforms to target a wide range of cancers.